Sanjeev Kumar

Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors

Sanjeev Kumar, William P. Malachowski, James B. DuHadaway et al. · Journal of Medicinal Chemistry · 2008 · 167 citations · Full text

Medicine, Oncology, Pharmacology +13

Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide

Sanjeev Kumar, Koppara Samuel, Matthew P. Braun et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 165 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase

Sanjeev Kumar, Daniel Jaller, Bhumika Patel et al. · Journal of Medicinal Chemistry · 2008 · 149 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

Mario R. Mautino, Firoz A. Jaipuri, Jesse P. Waldo et al. · Cancer Research · 2013 · 86 citations

Medicine, Oncology, Pharmacology +10